ArticleNature medicine2024
A candidate antibody drug for prevention of malaria.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 46 citations in OpenAlex.
- Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial.PLoS medicine · 2026Trial
- Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet (London, England) · 2026Trial
- Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infection.JCI insight · 2024Trial
- Equitable access to monoclonal antibodies targeting parasites.Trends in parasitology · 2026Review
- Overcoming immunogenic gaps in malaria subunit vaccines by broadening CSP regions targeted.The Journal of experimental medicine · 2026Article
- Zoonotic Parasite Nanovaccines: Progress, Challenges, and Future Perspectives.Integrative zoology · 2026Review
- CRISPR-mediated precise large fragment insertion in zygotes enables rapid generation of humanized immunoglobulin heavy-chain mice.Immunity · 2026Article
- Anti-malaria antibody engineering broadens recognition motifs and reveals new homotypic interactions that enhance protective breadth.Nature communications · 2026Article
- htrSPRanalysis: An open source R package for expedited analysis of high-throughput binding kinetics data.PLoS computational biology · 2026Article
- Malaria Prevention: Progress to Date.Drugs · 2026Review
- Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines.Malaria journal · 2026Article
- Relevance of the antibody Fc fragment and epitope valency in protection against malaria sporozoites.EMBO reports · 2026Article
- Structural basis for conserved and distinct antigen recognition by a lineage of malaria-protective antibodies.PLoS pathogens · 2026Article
- Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21.NPJ vaccines · 2026Article
- Recent Advances, Bottlenecks, and Future Directions inVaccines · 2026Review
- Plant-produced monoclonal antibodies recognize the native circumsporozoite protein onBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments.Pathogens (Basel, Switzerland) · 2026Review
- Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies.Frontiers in immunology · 2026Article
- Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials.Frontiers in immunology · 2026Article
- Machine learning enables de novo multiepitope design ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
- Commented on by
Authors and funding
30 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over 75% of malaria-attributable deaths occur in children under the age of 5 years. However, the first malaria vaccine recommended by the World Health Organization (WHO) for pediatric use, RTS,S/AS01 (Mosquirix), has modest efficacy. Complementary strategies, including monoclonal antibodies, will be important in efforts to eradicate malaria. Here we characterize the circulating B cell repertoires of 45 RTS,S/AS01 vaccinees and discover monoclonal antibodies for development as potential therapeutics. We generated >28,000 antibody sequences and tested 481 antibodies for binding activity and 125 antibodies for antimalaria activity in vivo. Through these analyses we identified correlations suggesting that sequences in Plasmodium falciparum circumsporozoite protein, the target antigen in RTS,S/AS01, may induce immunodominant antibody responses that limit more protective, but subdominant, responses. Using binding studies, mouse malaria models, biomanufacturing assessments and protein stability assays, we selected AB-000224 and AB-007088 for advancement as a clinical lead and backup. We engineered the variable domains (Fv) of both antibodies to enable low-cost manufacturing at scale for distribution to pediatric populations, in alignment with WHO's preferred product guidelines. The engineered clone with the optimal manufacturing and drug property profile, MAM01, was advanced into clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.